Novel insights into the biology and treatment of chronic myeloproliferative neoplasmsFootnote

^*Dedicated to John M. Goldman.

References

• Mughal TI, Vannucchi AM, Soverini S, et al. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica 2014;99:797–803.
   PubMed Web of Science ®Google Scholar
• Druker B, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1042.
   PubMed Web of Science ®Google Scholar
• Cortes J, Hochhaus A, Kim DW, et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood. 2013;122(Suppl. 1): Abstract 65.
   Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Hughes T, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood 2013;122(Suppl. 1): Abstract 92.
   Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–1127.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798.
   PubMed Web of Science ®Google Scholar
• Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated geneomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123–e133.
   PubMed Web of Science ®Google Scholar
• Klampf T, Gisslinger H, Hanutyunyan A, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379–2390.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391–2405.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014;123:3714–3719.
   PubMed Web of Science ®Google Scholar
• Duek A, Lundberg P, Shimizu T, et al. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F driven mouse model of myeloproliferative neoplasms. Blood 2014;123: 3943–3950.
   PubMed Web of Science ®Google Scholar
• Mughal TI, Goldman JM. Why does CML evolve from a chronic phase to blast phase?Front Biosci 2006;1:198–208.
   Web of Science ®Google Scholar
• Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 2008;112:1628–1637.
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Ph-negative myeloproliferative neoplasms. Blood 2013;121:2725–2733.
   PubMed Web of Science ®Google Scholar
• Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012;119:4480–4485.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Crews LA, Barrett CL, et al. ADAR-1 promotes malignant progenitor programming in chronic myeloid leukemia. Proc Natl Acad Sci USA 2013;110:1041–1046.
   PubMed Web of Science ®Google Scholar
• Rampal R, Pandey S, Abdel-Wahab O, et al. Development of a murine model for leukemic transformation of myeloproliferative neoplasms for preclinical therapeutic studies. Blood 2012;120(Suppl. 1): Abstract 808.
   Web of Science ®Google Scholar
• Wang L, Swierczek SI, Lanikova L, et al. The relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera. Leukemia 2014;28:938–941.
   PubMed Web of Science ®Google Scholar
• Wang L, Swierczek SI, Drummond J, et al. Whole-exome sequencing of polycythemia vera revealed driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 2014;28: 935–938.
   PubMed Web of Science ®Google Scholar
• Kent D, Green AR. Order matters: mutation order influences tumour evolution and stem cell potency by altering transcriptional consequences of the second mutation. Haematologica 2014: EHA Abstract LBA2434.
   Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2008;85: 62–69.
   Web of Science ®Google Scholar
• Barosi G, Poletto V, Massa M, et al. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis. PLoS One 2013;8:e59791.
   Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006;19:413–437.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns?Histol Histopathol 2005; 20:633–644.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Mullauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011;117:5710–5718.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2014;89: 52–54.
   PubMed Web of Science ®Google Scholar
• Ejerblad E, Kvasnicka HM, Thiele J, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology 2013; 18:8–13.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 2013; 121:1720–1728.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Orazi A, et al. European LeukemiaNet (ELN) consensus criteria for therapy response based on bone marrow features in patients with myelofibrosis. J Clin Oncol to Leukemia (in press).
   Google Scholar
• Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272–4290.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89:199–202.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Reddy MM, Schade GOM, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26:708–715.
   PubMed Web of Science ®Google Scholar
• Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014;123:1372–1383.
   PubMed Web of Science ®Google Scholar
• Meyer S, Levine R. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 2014;20:2051–2059.
   PubMed Web of Science ®Google Scholar
• Andreoli A, Verger E, Robin M, et al. Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain. Blood 2013;122(Supp. 1): Abstract 1591.
   Web of Science ®Google Scholar
• Weigert O, Lane A, Bird J, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012;209:259–273.
   PubMed Web of Science ®Google Scholar
• Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterdimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155–159.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047–4053.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa R, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013;122(Suppl. 1): Abstract 396.
   Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013;122(Suppl. 1): Abstract 4055.
   Google Scholar
• Harrison CN, Cortes JE, Cervantes F, Mesa, et al. Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122(Suppl. 1): Abstract 393.
   Web of Science ®Google Scholar
• Mesa R, Cortes JE, Cervantes F, et al. Symptom burden and health-related quality of life (HRQoL) in patients with myelofibrosis (MF) treated with fedratinib (SAR302503) in a phase III study (JAKARTA). Blood 2013;122(Suppl. 1): Abstract 4061.
   Google Scholar
• Harrison C, Schaap NP, Zweegman S, et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate- or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: interim results from a phase II study (JAKARTA-2). Blood 2013;122(Suppl. 1): Abstract 661.
   Google Scholar
• Zhang Q, Zhang Y, Diamond S, et al. The Janus kinase 2 inhibtor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metab Dispos 2014;42: 1656–1662.
   PubMed Web of Science ®Google Scholar
• Dean JP, Cernohous P, Komrokji RS, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤ 100,000/μl. Blood 2013;122(Suppl. 1): Abstract 395.
   Web of Science ®Google Scholar
• Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322–1327.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Salama ME, et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013;122(Suppl. 1): Abstract 665.
   Google Scholar
• Pardanani A, Roberts AW, Seymour JF, et al. BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1/2a study in myelofibrosis. Blood2013;122(Suppl. 1): Abstract 664.
   Google Scholar
• Mascarenhas J, Talpaz M, Gupta V, et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013;122(Suppl. 1): Abstract 663.
   Google Scholar
• Tefferi A, Begna K, Laborde RR, et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. Blood 2013; 122(Suppl. 1): Abstract 662.
   Web of Science ®Google Scholar
• Birgegard G. Does anything work for anemia in myelofibrosis?Best Pract Res Clin Haematol 2014;27:175–185.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal therapy?Clin Cancer Res 2014;20:310–322.
   PubMed Web of Science ®Google Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439–4442.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Soverini S. Molecular response in CML: where is the bar?Blood 2014; 124:469–471.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinb, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014;32:415–423.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014:123:1309–1318.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Bumm TG, Corbin AS, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 2008;112:1960–1970.
   PubMed Web of Science ®Google Scholar
• Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. J Cell Physiol 2014 Sep 10. [Epub ahead of print]
   Google Scholar
• Stein BL, Swords R, Hochhaus A, et al. Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia 2014 Jun 3. [Epub ahead of print]
   Google Scholar